Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;76(8):2605-2607.
doi: 10.1111/all.14839. Epub 2021 Apr 22.

Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing

Leonardo Bianchi  1 , Filippo Biondi  1 , Katharina Hansel  1 , Nicola Murgia  2 , Marta Tramontana  1 , Luca Stingeni  1
Affiliations

Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing

Leonardo Bianchi et al. Allergy. 2021 Aug.
No abstract available

Keywords: SARS-CoV-2 vaccine; adverse drug reaction; intradermal test; skin test.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

FIGURE 1
FIGURE 1
Intradermal test (IDT) with Pfizer‐BioNTech vaccine. Erythematosus, oedematous and infiltrated reaction at 24 h inpatient 1 (A) and in a healthcare volunteer who had received the first dose of Pfizer‐BioNTech vaccine (B). Negative IDT in a not‐vaccinated volunteer (C)
See this image and copyright information in PMC

References

    1. Shimabukuro T, Nair N. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer‐BioNTech COVID‐19 Vaccine. JAMA 2021;325(8):780. - PMC - PubMed
    1. Center for Disease Control and Prevention. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer‐BioNTech COVID‐19 Vaccine — United States; December 14–23, 2020. https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm. Accessed February 17, 2021.
    1. Caballero ML, Quirce S. Excipients as potential agents of anaphylaxis in vaccines: analyzing the formulations of the current authorized COVID‐19 vaccines. J Investig Allergol Clin Immunol. 2021;31(1):92–93. 10.18176/jiaci.0667 - DOI - PubMed
    1. Sokolowska M, Eiwegger T, Ollert M, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines. Allergy. 2021;76(6):1629–1639. - PMC - PubMed
    1. Worm M, Bauer A, Wedi B, et al. Practical recommendations for the allergological risk assessment of the COVID‐19 vaccination ‐ a harmonized statement of allergy centers in Germany. Allergol Select. 2021;26(5):72‐76. - PMC - PubMed

Substances